Status:
COMPLETED
Study of a Behavioral Intervention for Older Advanced Cancer Patients and Their Caregivers
Lead Sponsor:
University of Rochester
Collaborating Sponsors:
National Cancer Institute (NCI)
National Institute on Aging (NIA)
Conditions:
Cancer, Advanced
Cognitive Impairment, Mild
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
The purpose of this study is to test the feasibility of a telehealth Dyadic Life Review (DLR), adapted from individual Life Review Therapy, with patients and caregivers of older adults with advanced c...
Eligibility Criteria
Inclusion
- Patient
- Age ≥ 65
- Able to provide informed consent. All patients will be assessed using the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC) 56 - a score \>14.5 will define ability to independently provide informed consent.
- Eligible patients have Stage III or IV cancer of any type
- Additionally, at least 20 patients will have a will have a high likelihood of MCI based on screening score of \<26 on the Montreal Cognitive Assessment (MoCA) within their eRecord chart.
- Able to read and understand English
- Patient
Exclusion
- Patients scoring \<14.5 on the UBACC
- Unable to identify caregiver to participate in study
- Caregiver Inclusion Criteria:
- One caregiver for each patient will be eligible and must be chosen by the patient. For the purposes of this study, a caregiver is defined as a valued and trusted person in a patient's life who is supportive in health care matters by providing valuable social support and/or direct assistive care.
- Caregivers will be selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters;" patients who cannot identify such a person ("caregiver") will remain eligible for the study.
- Age 50 or older
- Ability to provide consent
- Proficient in English
- Caregiver Exclusion Criteria
- Caregivers unable to understand the consent form due to cognitive, health or sensory impairment will be excluded
Key Trial Info
Start Date :
March 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 24 2024
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT05200572
Start Date
March 28 2022
End Date
May 24 2024
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rochester Medical Center
Rochester, New York, United States, 14642